Clinical Trials Browser

Phase 3 × Abiraterone Acetate × 90 days × Clear all

NCT02257736 2026-03-19

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 3 Active not recruiting

982 enrolled 15 charts

Prostatic Neoplasms

NCT03748641 2026-03-16

MAGNITUDE

Phase 3 Active not recruiting

765 enrolled 16 charts 1 FDA

Prostatic Neoplasms, Castration-Resistant

NCT05171816 2026-03-11

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

Phase 3 Active not recruiting

110 enrolled 12 charts

Metastatic Castration-resistant Prostate Cancer

NCT06136624 2026-03-11

OMAHA-003

Phase 3 Recruiting

Prostate Cancer Metastatic

NCT06136650 2026-03-09

MK-5684-004

Phase 3 Recruiting

Prostatic Neoplasms

NCT07213674 2026-02-27

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Phase 3 Recruiting

Prostatic Neoplasms

NCT04497844 2026-02-13

AMPLITUDE

Phase 3 Active not recruiting

696 enrolled 15 charts 1 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT06120491 2026-01-21

EvoPAR-PR01

Phase 3 Recruiting

Prostatic Neoplasms

NCT04493853 2026-01-20

CAPItello-281

Phase 3 Active not recruiting

Prostatic Neoplasms